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Abstract
Pericytes have the potential to be developed as a cell therapy for the treatment of wounds; how-
ever, the efficacy of any cell therapy relies on the successful delivery of intact and functioning cells.
Here, the effect of delivering pericytes on wound repair was assessed alongside the development
of a surface-functionalized pericyte patch. Plasma polymerization (PP) was used to functionalize the
surface of silicone patches with heptylamine (HA) or acrylic acid (AA) monomers. Human pericytes
were subsequently delivered to murine excisional wounds by intradermal injection or using the
pericyte-laden patches and the comparative effects on wound healing, inflammation and revascu-
larization determined. The AA surface provided the superior transfer of the cells to de-epidermized
dermis. Excisional murine wounds treated either with pericytes injected directly into the wound or
with the pericyte-laden AA patches showed improved healing with decreased neutrophil infiltration
and reduced numbers of macrophages in the wounds. Pericyte delivery also enhanced angiogene-
sis through a mechanism independent of VEGF signalling. Pericytes, when delivered to wounds,
improved healing responses by dampening inflammation and promoting angiogenesis. Delivery of
pericytes using PP-AA-functionalized patches was equally as effective as direct injection of peri-
cytes into wounds. Pericyte-functionalized dressings may therefore be a clinically relevant ap-
proach for the treatment of wounds.
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Introduction
The identification of cells that possess attributes that will enhance
wound healing has been a long-term goal for the development of cell
therapies. Pericytes are one such cell that has been considered for
the treatment of muscle, bone and heart injuries [1–3], but pericyte
effectiveness as a cell therapy for the treatment of wounds has yet to
be determined. Pericytes are peri-vascular mesenchymal stem cell
(MSC)-like cells involved in the regulation of both vascularization
and inflammation, which have been shown to be important contrib-
utors to a number of processes important for successful wound heal-
ing [4, 5]. Pericyte presence on or near vascular structures regulates
the infiltration of leukocytes from the blood stream to the site of
injury [6, 7] and consequently is important in mediating the balance
between an appropriate inflammatory response and the tissue dam-
age which can result if this response is too severe. Pericytes are also
important regulators of angiogenic activity and impact the capacity
of a tissue to successfully re-vascularize after injury [8].
In diabetic patients, many tissues exhibit a decrease in pericyte
populations, and this reduction has been implicated in the progres-
sion of some diabetic pathologies including diabetic foot ulcers [9].
Given that pericyte depletion is observed in the skeletal muscle of di-
abetic feet [10], it is possible that pericytes may also play a role in
contributing to the delayed cutaneous healing experienced by dia-
betic patients. As a result, we have hypothesized that pericytes
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represent a population of cells which are beneficial for cutaneous
healing and have the potential for development as candidates for the
treatment of wounds.
The identification and characterization of beneficial cell types is
not the only step in developing a successful cell therapy. A cell-based
product must be efficiently delivered to the site of intended action,
and difficulties in this process have the potential to impact the via-
bility or efficacy of the intended therapy [11]. The simplest and
most direct method of cell delivery is by injection immediately at the
site of injury. This approach has been utilized in the preclinical and
clinical testing of many cell therapies [12–14] and confers the benefit
of allowing direct application of the cells to the intended location
without relying on the cell itself to identify and reach the site of in-
jury. There are downfalls to this delivery method however, as injec-
tion of cells has been shown to decrease cell viability. In fact,
pushing cells through a syringe or needle has in some cases resulted
in cell viabilities of only 1–32% [15]. The manual stress of syringe
delivery can cause irreversible and sometimes fatal damage to the
cell membrane [16]: not only does this negate the potential benefit
of the cell therapy but also the introduction of a large population of
apoptotic or necrotic cells may serve to elicit an immune response
which could be detrimental to the healing process. Additionally, bio-
mechanical stress can induce the secretion of pro-inflammatory fac-
tors in some cell types, such as MSCs [17]. Hydrogels [18], scaffolds
[19], collagen plugs [20] and cell sheets [21], have previously been
explored as alternatives to injection. Another possible method of
cell delivery to the skin is by way of culturing the cells on a surface
which will support their survival and can be applied, much like a
dressing. Unlike injections, which are often applied around the mar-
gins of the wound, treatment with a dressing can have the additional
benefit of supplying cells to the whole of the wounds without having
to rely on cell migration into the wound site. Application of a cell-
coated surface to an open wound can facilitate transfer of the cells
from the surface into the wound bed, provided that the surface is
tuned such that the cells will find the skin preferable and move from
the surface into the wound. One way of functionalizing such surfa-
ces is by plasma polymerization (PP) [22]. This is a process which
distributes a chosen monomer in an even coating onto a surface, and
can be used to coat medically approved silicone surfaces in a short
time at a low cost [23]. The effects that surface chemistries can have
on pericyte adhesion and proliferation have been investigated using
plasma treatment and ion radiation [24]. There are, however, no
studies to date where plasma polymerization has been used to de-
posit monomers onto a surface to improve adherence of pericytes
and to then deliver the pericytes onto the surface of the skin or into
a wound. Keratinocytes [25], MSCs [26], corneal epithelial cells
[27] and multipotent adult progenitor cells (MAPCs) [28] have all
been successfully delivered on PP-functionalized silicone to planar
biological surfaces in pre-clinical murine trials. In this study, we cul-
tured human pericytes on PP-functionalized surfaces and assessed
the benefits of this method for pericyte delivery to wounds in com-
parison with direct injection.
Materials and methods
Preparation of plasma-polymerized patches
In order to develop a more clinically acceptable method of pericyte
administration, plasma polymerization (PP) was used to create func-
tionalized surfaces on silicone dressings, on which pericytes could be
grown and delivered. Heptylamine (HA) and acrylic acid (AA)
monomers were used to create amine-based and acid-based
polymers on the surfaces. Silicone backing (Polymer Systems
Technology, High Wycombe, UK) was cut into 15 mm  15 mm
squares and placed in a petri dish. The dish was placed in the cham-
ber of a parallel plate reactor. Plasma polymerization was performed
as previously described [28]. Briefly, following degassing with three
freeze–thaw cycles, polymerization was carried out using precursors
acrylic acid (AA) or heptylamine (HA) (Sigma Aldrich, Castle Hill,
NSW, Australia). A rotary pump was used to evacuate the reaction
chamber to a base pressure of less than 1104mbar. With an ini-
tial reaction pressure of 21 0 2 mbar, deposition was carried out
for 20 mins at a power of 5 W. Samples were stored in sealed petri
dishes for analysis and subsequent use.
X-ray photoelectron spectroscopy
To determine the predominate residues present on the surface of the
plasma-functionalized patches, a SPECS SAGE X-ray photoelectron
spectroscopy (XPS) system was used to obtain X-ray photo-electron
spectra with an Mg Ka radiation source operating at 10 kV and
20 mA. A survey spectrum between 0 and 1000 eV was taken to as-
sess all elements present on the sample surface. High-resolution
spectra were subsequently taken for selected peaks. Processing and
deconvolution of the spectra were carried out using CasaXPS soft-
ware (Neal Fairley, UK).
Cell culture
Human placental pericytes (hPC-PL) (Promocell, Heidelberg,
Germany) were cultured in pericyte media (Promocell, Heidelberg,
Germany) supplemented with 1% penicillin streptomycin (Sigma
Aldrich, Castle Hill, NSW, Australia) and maintained at 37C with
5% CO2.
MTT transfer assay
hPC-PLs at the density of 1105 were seeded in stainless steel rings
on patches in a 6-well plate (Corning, New York, USA) and allowed
to grow for 24 hours. The stainless steel rings and media were re-
moved and 2 ml of 0.5 mg/mL MTT reagent (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide) (Life Technologies
Australia, Scoresby, VIC, Australia) in PBS was added to each well.
The cells were incubated for 4 h at 37C to assess the metabolic ac-
tivity of cells on each patch. To assess the capacity of each patch for
cell transfer to skin in vitro, cells were seeded on patches as de-
scribed above and grown for 24 h. De-epidermized human acellular
dermis (DED) was obtained from the European Skin Bank and pre-
pared with three overnight PBS washes followed by one-hour incu-
bation at 37C in 1 M sodium chloride solution to remove the
epidermis and preserve membrane proteins. The DED was rehy-
drated in Dulbecco’s modified eagle media (DMEM) (Gibco,
Thermo Fisher Scientific, Scoresby, VIC, Australia), cut into 15 mm
15 mm squares and placed in a 6-well plate. Pericyte-laden
patches were placed carefully face down on the DED and weighted
with a stainless steel ring to ensure continued contact. Wells were
filled with 2 ml media and left for 24 h after which the rings were re-
moved, the patches carefully lifted from the DED and placed in
clean wells. 2 ml of 0.5 mg/mL MTT reagent was added to each well
and incubated for 4 h at 37C to assess the transferred patches and
DED for the presence of metabolically active pericytes.
Pericyte delivery to murine excisional wounds
These studies were conducted with approval from the Women’s and
Children’s Health Network (WCHN) Animal Ethics Committee
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(AEC) and carried out at the WCHN animal facility in keeping with
the Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes (AEC: 1090.05.2021). Twelve-week-old Balb/C
female mice from the Animal Resources Centre (ARC) (Canning
Vale, WA, Australia) were acclimatized for 1 week prior to exci-
sional wounds being created as described previously [29]. Briefly,
following anaesthesia, the dorsa of mice were shaved, treated with
Veet and swabbed with ethanol to remove all hair. Two 6-mm full-
thickness wounds were created using a 6 mm Acu-Punch Biopsy
Punch (EBOS, Kingsgrove, NSW, Australia) 5 mm either side of the
midline and 10 mm from the base of the skull. Pericytes (hPC-PL)
were applied to the excisional wounds immediately after wounding
by way of injection or patch application. Pericytes for injection were
suspended in PBS (either 2104 or 8104 cells in 100ml) and
injected intradermally at four points (25ml/injection) around the pe-
riphery of the wound immediately after surgery using a 22 G needle.
Control wounds were injected with an equivalent volume of PBS
alone. Injected wounds were covered with Tegaderm (3 M, North
Ryde, NSW, Australia) for 3 days, after which the dressing was re-
moved. Pericytes for patch application were pipetted into stainless
steel rings on patches (2104 or 8104 cells/patch) 24 h prior to
surgery. The patches were applied cell-side down to the wound im-
mediately after surgery and affixed to the dorsa of the mice with
Tegaderm dressing. The patch and dressing remained for 3 days, af-
ter which they were removed. Any mice who lifted or removed their
patches/dressings during the first 3 days were anaesthetized and the
patches restored. Wounds were left to heal for 7 days and then col-
lected for analysis (n¼6 mice, 12 wounds for each treatment
group).
Wound measurement
On the day of surgery and wound collection, a ruler was aligned
with each wound and digital images were collected to allow the
measurement of macroscopic wound area. Images were imported
into Image ProPlus (Media Cybernetics Inc., Bethesda, MD, USA)
software, and measurement tools were calibrated for each image us-
ing the ruler in the frame. Wound area at the time of collection (Day
7) was measured, normalized to the original wound area measured
and mean macroscopic wound area calculated for each group.
Histological wound analysis was carried out manually using cellSens
software (Olympus, Tokyo, Japan). Bright-field images of haema-
toxylin and eosin-stained sections were assessed for dermal wound
width and the extent of re-epithelialization. Wound width was de-
fined as the measurement between the left and right outer edges of
the dermal wound area. Re-epithelialization was calculated as the
percentage of the total epithelial length covered by the two migrat-
ing tongues of the neoepidermis. Mean microscopic wound width
and re-epithelialization measurements were calculated for each
group.
Immunofluorescence
Sections were deparaffinized in two 15-min changes of xylene and
brought to water through two 2-min changes in absolute EtOH,
2 min in 70% EtOH, 2 min in 30% EtOH and 4 min in tap water.
Sections were washed in PBS and transferred to a decloaker (Biocare
Medical, Pacheco, CA, USA) for antigen retrieval (heating in citric
acid buffer at 90C for 10 min) followed by a 3 min immersion in
0.25 g/L trypsin (Sigma Aldrich, Castle Hill, NSW, Australia) in PBS
at 37C. Sections were washed in PBS and then blocked for 1 h in
3% serum (Sigma Aldrich, Castle Hill, NSW, Australia) in PBS,
with the source of the serum corresponding to the species in which
the intended secondary antibody was raised. The blocking solution
was then replaced with the primary antibody: NIMP Santa Cruz sc-
59338 Rat 1:200, F4/80 Bio-Rad MCA4975 Rat 1:200, VEGF
Abcam ab46154 Rabbit 1:200, CD31 Abcam ab28364 Rabbit
1:200 or HNA Abcam ab190710 Mouse 1:200 diluted in 3% serum,
and sections were left to incubate overnight at 4C. Sections were
subsequently washed three times for 5 min in PBS and then incu-
bated for 1 h at room temperature in secondary antibody diluted in
PBS. Sections were stained for 5 min in 1:5000 40,6-diamidino-2-
phenylindole (DAPI) (Sigma Aldrich, Castle Hill, NSW, Australia)
in PBS, washed three times for 5 min in PBS, dried and mounted in
PermaFluor mounting media (Thermo Fisher Scientific, Scoresby,
VIC, Australia). Stitched images of the entire wound area were ac-
quired for each sample and analysed using cellSens software. For in-
tensity measurements, mean grey intensity was measured across the
wound bed and the auto-fluorescent measurement taken from a
matched no primary control section was subtracted. For cell counts,
the area of interest was manually defined and measured. The num-
ber of positive cells within the area of interest was manually counted
and then normalized to the area measurement for each sample.
Mean measurements were calculated for each wound group. Human
skin samples were used as positive controls for HNA staining.
Human skin samples were collected from patients at the Queen
Elizabeth Hospital with approval from the Health Service Human
Research Ethics Committee and the Central Northern Adelaide
Health Service Ethics of Human Research Committee (EC00190).
All studies were carried out in accordance with the Declaration of
Helsinki (1964).
Statistical analysis
For macroscopic comparisons between pericyte treatment and con-
trol groups, statistical significance was calculated using a two-way
ANOVA with multiple comparisons. For histological and immuno-
histochemical comparisons between these wounds, statistical signifi-
cance was calculated using a Student’s t-test. Annotation of
significance above any treatment group indicates statistical signifi-
cance between that treatment and the relevant control group. For all
analyses, any P values of <0.05 were considered significant.
Graphical representation of significance: *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001. All data are displayed as mean 6
SEM.
Results
Pericytes injected into acute wounds improve healing
In order to be able to compare the efficacy of pericytes delivered by
PP-functionalized patches to those directly injected into wounds, we
first performed an assessment of direct injection into murine exci-
sional wounds. Commercially available human pericytes of placen-
tal origin (hPC-PL) were delivered to excisional wounds in Balb/C
mice by intradermal injection. Wounds received either 2104 cells
in PBS (low dose), 8104 cells in PBS (high dose) or a control injec-
tion of PBS only immediately after wounding, at four sites around
the periphery of the wound. Wounds were covered with a Tegaderm
dressing for 3 days, after which the dressing was removed.
Macroscopic measurements of wound area were calculated from
images taken at Days 3 and 7 and normalized to original wound size
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for each sample (Fig. 1a and b). Wounds injected with both low and
high cell doses displayed a significant acceleration in wound closure
compared to the PBS-injected control wounds: both treatment groups
displayed significantly smaller macroscopic wound areas than the PBS
control at Days 3 and 7 of healing. At Day 7, the average wound area
of the high-dose treatment group was significantly reduced (11.96%
of initial wound area) compared to that of the low-dose-treated
wounds (20.64%) and PBS control (29.02%). Histological assessment
of dermal wound width in haematoxylin and eosin-stained paraffin-
embedded Day 7 wounds (Fig. 1c) revealed that wound width was sig-
nificantly decreased in both the low- and high-dose treatment groups
when compared to the PBS control group (Fig. 1d). While wound area
and width measurements suggested improved healing, there was no
specific effect on % re-epithelialization at Day 7 post-wounding (Fig.
1e). Staining of paraffin-embedded Day 7 wounds with an anti-human
nucleoli antibody (HNA) allowed visualization of the human pericytes
within the murine wounds. Both low- and high-dose-injected wounds
displayed the presence of HNA-positive cells in the wound bed, con-
firming pericytes delivered at Day 0 remained in the wound site until
at least 7 days after injection (Fig. 1f).
Plasma-polymerized silicone patches functionalized
with acrylic acid effectively transfer pericytes to human
skin in vitro
X-ray photoelectron spectroscopy (XPS) was used to characterize
and verify the plasma polymer surface coatings (Table 1).
Heptylamine (HA) plasma polymer is most easily confirmed by the
presence of nitrogen as shown by an N1s peak at 399eV and the sup-
pression of silicon from the underlying silicone rubber. Previous char-
acterization of the HA plasma polymer reported the N/C ratio of 0.05
at 5 W [28], and this analysis shows a similar ratio of 0.052. Similarly,
acrylic acid (AA) plasma polymer has a reported O/C ratio of 0.36 at
5 W, and this analysis shows a similar ratio of 0.31. Furthermore, the
characteristic carboxyl and alcohols are present upon deconvolution
of the high-resolution C1s spectra (Supplementary Figure S1). The
presence of silicon is typical due to the mobility of the silicone chains
in the underlying rubber, the percentage of which can change slightly
as the polymer ages. This characteristic was previously reported and
had little-to-no effect on the utility of the polymer surface [28].
Each surface was assessed for the capacity to support the attach-
ment and survival of pericytes in culture using a metabolic MTT assay.
Cell-coated PP-functionalized patches (Fig. 2a) were applied to de-epi-
dermized acellular human dermis (DED) in an in vitro model of appli-
cation to skin in order to investigate the ability of the pericytes to move
from the functionalized surface of the PP-patch to the skin. Transfer
assays indicated that the chemistry of both patches supported pericyte
survival for 24 h (Fig. 2b and c). The application of HA PP-functional-
ized patches carrying pericytes to human DED did not result in efficient
transfer of the cells from the PP-functionalized patch to the skin. As the
cells also did not remain on the patch after transferring, it was assumed
that cells not adhered to the DED were washed off into the media (Fig.
2b). In contrast, the AA surface performed considerably better, facili-
tating effective overnight transfer of the pericytes to DED (Fig. 2c).
Consequently, the AA PP-functionalized patch was selected for non-in-
vasive pericyte delivery to murine wounds in vivo.
Plasma-polymerized acrylic acid patches effectively
deliver pericytes into wounds, resulting in improved
healing
hPC-PLs were delivered to excisional wounds of Balb/C mice using
AA PP-functionalized patches. hPC-PLs were cultured on the AA
PP-functionalized patches for 24 h prior to application to the
wounds. Wounds received either 2104 cells (low dose), 8104
cells (high dose) or a control AA patch alone, immediately after sur-
gery. The patches were secured with a Tegaderm dressing for 3 days,
after which the patch and dressing were removed. Macroscopic as-
sessment of wound size from images taken at Days 3 and 7 of heal-
ing (Fig. 3a and b) indicated that average wound area was
significantly reduced in the low-dose pericyte PP-functionalized-
patch-treated wounds at Days 3 (83.94%) and 7 (20.40%) (Fig. 3a
and b and Table 2). High-dose pericyte PP-functionalized-patch-
treated wounds were significantly smaller at Day 7 (22.08%) than
patch-alone control wounds (31.72%). There was no significant dif-
ference between the wound areas of the high- and low-dose groups
at Day 7 (Table 2). Histological measurements of haematoxylin and
eosin-stained paraffin-embedded Day 7 sections (Fig. 3c and d and
Table 2) indicated significantly decreased wound width in the low-
dose PP-functionalized patch treatment group; however, the width
of high-dose-patch-treated wounds was not significantly different to
the average width of the PP-functionalized patch-alone control
group (Fig. 3d and Table 2). Re-epithelialization was not impacted
by pericyte delivery on the PP-functionalized patches, with wounds
of all groups displaying comparable levels of epithelial restoration
by Day 7 (Fig. 3e and Table 2). HNA staining of Day 7 wounds con-
firmed successful delivery of human pericytes to the wound bed, as
HNA-positive cells were present in the wounds of both low- and
high-pericyte PP-functionalized patch treatment groups (Fig. 3f and
Table 2).
Plasma-polymerized acrylic acid pericyte patches
decrease inflammation in wounds
Immunofluorescent staining was employed to assess the impact of
pericyte delivery either by injection or by PP-functionalized patch on
wound inflammation. NIMP-R14 staining was used to quantify neu-
trophil infiltration in pericyte-injected and PP-functionalized-patch-
treated Day 7 wounds (Fig. 4a–c). Neutrophil numbers were
counted and normalized to wound area for each sample. Pericyte-
injected wounds displayed significantly decreased neutrophil num-
bers in the granulation tissue at Day 7 when compared to PBS-
treated control wounds (Fig. 4a and b). Pericyte-patch-treated
wounds also showed lower NIMP-R14-positive cells in the wounds
(Fig. 4a and c) indicating that neutrophil infiltration was lower in
pericyte PP-patch-treated wounds than patch-alone wounds at Day
7 (Fig. 4a and c). Macrophage infiltration was assessed using F4/80
staining (Fig. 4d), and cell counts were normalized to wound area
(Fig. 4e and f). Pericyte-injected wounds displayed a trend towards
decreased macrophage presence in the wound bed; however, this dif-
ference did not reach statistical significance (Fig. 4d and e). Pericyte
PP-functionalized-patch-treated wounds displayed significantly de-
creased macrophage numbers in the wound beds treated with
2104 cells when compared with patch-alone control wounds (Fig.
4d and f).
Plasma-polymerized acrylic acid pericyte patches
increase vascularization of wounds
The impact of pericyte injection and pericyte PP-functionalized
patch application on angiogenesis was assessed by immunohisto-
chemical staining of VEGF and CD31 in the granulation tissue of
the Day 7 wounds (Fig. 5). Staining was normalized to wound area
and compared between low- and high-dose pericytes as well as con-
trol wounds. VEGF expression was compared between injected
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Figure 1. Injection of pericytes improves healing of acute murine wounds. (a) Representative images of wounds injected with 2 104 pericytes, 8104 pericytes
or PBS alone, 3 and 7 days after wounding. Black scale bars represent 5 mm. (b) Quantification of macroscopic wound area. Statistical significance calculated by
two-way ANOVA, where *P< 0.05, ***P<0.001, ****P< 0.0001. (c) Haematoxylin and eosin-stained sections representative of wounds injected with 2104 peri-
cytes, 8104 pericytes or PBS alone, 7 days after wounding. Composite images captured at 10 objective, black scale bars represent 0.5 mm. (d) Quantification
of histological wound width. (e) Quantification of re-epithelialization calculated as a percentage of total epithelial length. Statistical significance calculated by
one-way ANOVA, where *P< 0.05, **P<0.01. (f) Images representative of HNA-positive (green) cells counterstained with DAPI (blue) in PBS control, 2104 and
8104 pericyte injected wounds, 7 days after wounding. Positive control: acute human wound sample. Images captured at 40 objective, white scale bars repre-
sent 20 lm. n¼6 for all groups, all data are represented as mean 6 SEM. Annotation of significance above any treatment group indicates statistical significance
between that treatment and the PBS control group at that time point
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pericytes and PBS-injected wounds (Fig. 5a–c) and showed no signif-
icant difference observed between VEGF levels in treated or control
wounds at Day 7 of healing (Fig. 5b). Similarly, pericyte delivery by
PP-functionalized patch did not significantly impact VEGF expres-
sion within the wound bed (Fig. 5c). Injection of pericytes resulted
in significantly increased CD31 expression in the wound bed when
compared to wounds injected with PBS alone (Fig. 5d and e), which
was statistically significant when the high dose (8104) of cells was
injected (Fig. 5e). When the pericytes were delivered using the PP-
functionalized patch, CD31 expression was significantly greater in
pericyte PP-functionalized patch-treated wounds with both the low
and high doses of cells when compared to control wounds (Fig. 5d
and f).
Discussion
The identification and development of cell therapies is an emerging
and rapidly expanding focus for regenerative medicine. As most dis-
eases and pathologies result from cellular death or dysfunction, us-
ing endogenous cells that have the capacity to contribute to tissue
regeneration may be a way to address these pathologies. In recent
years, pericytes have been identified as a potentially underutilized
cell population with the capacity to regulate the behaviour of other
cells and to regenerate cell populations of multiple lineages [30].
Pericytes have been applied to mouse models of bone and muscle in-
jury [1, 2], ischaemic heart [3] and diabetic retinopathy [31], and
show a promising capacity to contribute to the regeneration of these
tissues, consistently accelerating tissue repair and causing increased
revascularization. However, the identification of promising cells
that promote tissue regeneration and repair is only one part of the
solution: the method of cell delivery is a key aspect in the develop-
ment of a successful cell therapy [32]. Systemic methods of delivery
(e.g. intravenous, intraperitoneal or intraventricular injection) insert
cells into the circulation, and consequently therapeutic efficacy relies
on homing of those cells to the site of therapeutic need [33]. A
Table 1. Summary of XPS for surfaces generated using HA and AA
precursors
Monomer C1s O1s N1s Si2p O/C N/C COOH/R C-OH
HA 85.63 6.659 4.48 3.231 0.078 0.052
AA 65.577 20.341 0 14.082 0.31 12.99 10.45
Figure 2. Plasma-polymerized silicone patches functionalized with acrylic acid effectively transfer pericytes to human skin in vitro. (a) Plasma-polymerized sili-
cone patch. MTT transfer assay assessing hPC-PL delivery by (b) HA patch and (c) AA patch in vitro. Pictured are patches before transfer to DED, patches after
transfer to DED and DED after patch application. MTT staining (purple) indicates the presence of metabolically active cells
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Figure 3. AA PP-functionalized patch delivery of pericytes improves healing of acute murine wounds. (a) Representative images of wounds treated with 2 104
pericytes on PP-patch, 8 104 pericytes PP-patch or PP-patch alone, 3 and 7 days after wounding. Black scale bars represent 5 mm. (b) Quantification of macro-
scopic wound area. Statistical significance calculated by two-way ANOVA, where *P< 0.05. (c) Haematoxylin and eosin-stained sections representative of
wounds treated with pericyte PP-patch, 8104 pericyte PP-patch or PP-patch alone, 7 days after wounding. Composite images captured at 10 objective; black
scale bars represent 0.5 mm. (d) Quantification of histological wound width. (e) Quantification of re-epithelialization calculated as a percentage of total epithelial
length. Statistical significance calculated by one-way ANOVA, where *P< 0.05. (f) Images representative of HNAþ (green) cells counterstained with DAPI (blue) in
2104 pericytes on PP-patch, 8 104 pericytes PP-patch or PP-patch-alone-treated wounds. Positive control: acute human wound sample. Images captured at
40objective; white scale bars represent 20 lm. n¼ 6 for all groups. Annotation of significance above any treatment group indicates statistical significance be-
tween that treatment and the patch-alone control group at that time point
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preferred alternative is application of cells by injection directly to
the injured tissue, as this confers immediate local action [34]. Apart
from there being a significant level of efficacy, for clinical uptake of
new technologies there is the added requirement that cell treatments
are simple, requiring limited preparation and minimal training. The
development of cell-based dressings is therefore an attractive ap-
proach for the delivery of cells into wounds.
PP-functionalized silicone surfaces have previously been ex-
plored to facilitate the delivery of multiple cell types. While kerati-
nocytes and endothelial cells proliferate and migrate faster in
response to a surface rich in acidic groups, dermal fibroblasts and
MAPCs prefer an amine-based surface [22, 28]. Interestingly, while
this same HA-functionalized PP-patch supported the survival of
pericytes, it did not effectively transfer these cells to skin explants in
culture. In contrast, when pericytes were cultured on acid-based AA
patches, the cells survived and were efficiently transferred in vitro.
Human pericytes were subsequently delivered to murine excisional
wounds by both intradermal injection and use of the cell-laden
AA PP-functionalized patches and the effect on wound healing
determined.
Assessment of healing indicated that, independent of the method
of delivery, pericytes caused an improvement in the rate of wound
closure. Macroscopic wound area and histological wound width
were decreased in wounds treated with low and high doses of peri-
cytes. This may be due to differentiation of the pericytes into con-
tractile myofibroblasts, as pericytes have been shown to contribute
to this population of contractile cells [35, 36]. A previous study
reported the application of pericytes in a collagen I plug caused a de-
lay in dermal wound resolution [20], which contradicts the effects of
pericyte delivery observed in this study. These differences in the ef-
fect of pericyte application may be due to the different methods of
cell application and highlight the importance of the method of deliv-
ery: the insertion of collagen gels may have served to effectively stent
the closure of the wounds, an effect which was not at play when the
cells were administered by intradermal injection or delivered by PP-
functionalized patches. Whilst there was little difference in the re-
pair rates when the cells were treated either with pericyte injections
or with the pericyte PP-functionalized patches, differences may oc-
cur when larger, or more complex wounds are investigated. In larger
wounds, pericytes delivered via injection may be limited by the
distance and they are able to migrate into the wound limiting their
effectiveness whilst cell patches would deliver pericytes throughout
the wounds. Pericyte-laden PP-functionalized patches could also, po-
tentially, be frozen and stored for later use [37], which would
greatly improve their usability in the clinic. While cell suspensions
could also be used in the clinic, they generally contain significant
volumes of DMSO, which can be toxic in wounds and would also
require specially trained staff and equipment to prepare the cells for
injection.
Re-epithelialization of wounds was not significantly affected by
pericyte delivery by injection or PP-functionalized patches. In vitro
studies have shown paracrine pericyte regulation of epithelial resto-
ration by way of BMP-2 signalling, with increased pericyte presence
in the dermal layer of organotypic cultures promoting accelerating
formation of the epidermis [38]. The discrepancy between pericyte
impact on epithelialization in vitro and in vivo may be due to an
inability of delivered human pericytes to effectively signal and
communicate with the endogenous murine cells of the wound
environment.
Quantification of neutrophil and macrophage numbers in peri-
cyte-treated wounds, delivered either by injection or by PP-function-
alized patch, showed a reduction in inflammation. Endogenous
pericytes regulate neutrophil extravazation in a number of tissues by
remodelling the basement membrane of the blood vessel wall [6, 7],
and delivery of exogenous pericytes to a murine model of the ischae-
mic heart decreases macrophage infiltration at the site of injury [3].
This capacity of pericytes to dampen inflammation has the potential
to be of significant benefit during cutaneous healing, particularly in
chronic wounds where excessive inflammation contributes to im-
paired healing [39].
Enhanced angiogenesis was also a feature of the wounds treated
with pericytes delivered either by injection or on the PP-functional-
ized patches, with significantly greater expression of endothelial
marker CD31 observed. This increase in CD31-positive endothelial
cells is likely to be in response to either physical pericyte presence or
paracrine signalling and suggests that increased pericyte presence
alone can affect positive change in levels of wound angiogenesis.
Other studies have delivered adipose-derived stem cells expressing
perivascular markers aSMA, PDGFRb, NG2 and Ang1 to rat
wounds using fibrin gels and reported similar vascular benefits [40].
Table 2. Assessment of excisional wound healing in mice treated with pericytes injections and patch-coated pericytes
Healing assessment Injection treatment Patch treatment
Macroscopic wound area (% initial wound) Groups Day 7 Groups Day 7
PBS control 29.02 6 2.82 Patch control 31.72 6 3.27
2  104 injection 20.64 6 3.04 2  104 patch 20.40 6 2.39
P values 0.0336 P values 0.0109
8  104 injection 11.96 6 2.35 8  104 patch 22.08 6 3.11
P value < 0.0001 P value 0.0343
Microscopic wound width (mm) PBS control 2.75 6 0.12 Patch control 2.77 6 0.20
2  104 injection 1.44 6 0.32 2  104 patch 1.90 6 0.16
P value 0.0013 P values 0.0111
8  104 injection 1.97 6 0.10 8  104 patch 2.12 6 0.19
P value 0.0431 P values 0.0581
Re-epithelialization (%) PBS control 86.70 6 8.94 Patch control 92.48 6 5.46
2  104 injection 77.11 6 12.93 2  104 patch 80.91 6 10.68
P value 0.8129 P values 0.5627
8  104 injection 73.66 6 10.70 8  104 patch 79.65 6 6.40
P value 0.6848 P values 0.4958
Data are presented as mean 6 SEM.
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Figure 4. Effect of pericyte treatment on inflammatory cell markers in acute wounds. (a) Immunofluorescent detection of neutrophils by NIMP-R14 (green) coun-
terstained with DAPI (blue) in Day 7 excisional wound sections treated with 2104 and 8 104 pericytes delivered either by injection or by PP-patch. (b)
Quantification of NIMP-R14-positive neutrophils normalized to area in the wounds treated by pericyte injection. (c) Quantification of NIMP-R14-positive neutro-
phils normalized to area in the wounds treated by pericyte PP-patch. (d) Immunofluorescent detection of macrophages by F4/80 staining (green) counterstained
with DAPI (blue) in Day 7 excisional wound sections treated with 2104 and 8104 pericytes delivered either by injection or by PP-patch. (e) Quantification of
F4/80-positive macrophages normalized to area in the wounds treated by pericyte injection. (f) Quantification of F4/80-positive macrophages normalized to area
in the wounds treated by pericyte PP-patch. n¼6 for all groups, all data are represented as mean 6 SEM. Statistical significance calculated by Student’s t-test,
where *P<0.05, **P<0.01. Annotation of significance above the treatment group indicates statistical significance between that treatment and the PBS control
group at that time point. Images captured at 40 objective; white scale bars represent 20 lm
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Figure 5. Effect of pericyte treatment on angiogenesis in acute wounds. (a) Immunofluorescent detection of CD31-positive endothelial cells (orange) counter-
stained with DAPI (blue) in Day 7 excisional wound sections treated with 2104 and 8 104 pericytes delivered either by injection or by PP-patch. (b)
Quantification of CD31-positive cells normalized to area in the wounds treated by pericyte injection. (c) Quantification of CD31-positive cells in the wounds treated
by pericyte PP-patch. (d) Immunofluorescent detection of VEGF (orange) counterstained with DAPI (blue) in Day 7 excisional wound sections treated with 2104
and 8 104 pericytes delivered either by injection or by PP-patch. (e) Quantification of VEGF treated by pericyte injection. (f) Quantification of VEGF in the wounds
treated by pericyte PP-patch. n¼ 6 for all groups, all data are represented as mean 6SEM. Statistical significance calculated by Student’s t-test, where *P<0.05,
**P< 0.01. Annotation of significance above the treatment group indicates statistical significance between that treatment and the PBS control group at that time
point. Images captured at 40 objective, white scale bars represent 20 lm
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Enhanced neo-vascularization has also been observed in wounds
treated with pericyte cell sheets and human umbilical cord perivas-
cular cells (HUCPVCs) [41, 42]. Interestingly, VEGF expression was
found to be unchanged in wounds treated with pericytes, indicating
that pericyte delivery did not alter the expression of this pro-angio-
genic signal within the wound bed. Pericytes have been reported to
support the stabilization of vascular structures [43], and we have
previously shown in vitro that this stabilization is in part physical
and cannot be achieved through the delivery of pericyte-conditioned
media alone [44], supporting the notion that delivery of an increased
pericyte population may support the accumulation of stabilized ves-
sels over the course of healing and enhance angiogenesis and revas-
cularization through a mechanism independent of VEGF signalling.
This study has shown that pericytes have the potential to im-
prove healing responses by dampening inflammation and promoting
angiogenesis. The delivery of pericytes using AA PP-functionalized
patches was equally as effective as direct injection of the cells into
the wounds. The development of pericyte-based cell dressings may
be a clinically relevant approach for the treatment of wounds which
does not require injection.
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